|
목적 : To assess the change in subfoveal choroidal thickness (SFCT) and total choroidal volume in central serous chorioretinopathy (CSC) following spontaneous resolution and intravitreal bevacizumab(Avastin) using the enhanced depth imaging optical coherence tomography (EDI-OCT).
방법 : A total of 10 consecutive eyes of 10 patients were included in this retrospective study: 5 eyes with spontaneously resolved CSC and 5 eyes with intravitreal bevacizumab(Avastin) treated CSC. Choroidal thickness and total mean choroidal volume was measured with enhanced depth imaging– optical coherence tomography (EDI–OCT) before and after intravitreal bevacizumab treatment. Mean choroidal volume measurements on the Early Treatment Diabetic Retinopathy Study (ETDRS) layout and squared sector grids were obtained by 3-dimensional raster scanning using SD-OCT.
결과 : SFCT of patients was 447.75±11.46μm at the baseline, and decreased 419±7.72 μm after a spontaneous resolution.(P=0.068) SFCT in IVB group was also reduced from 442.25±37.09 to 387.75±32.16μm.(P=0.068) Mean choroidal volume decreased from 10.86±0.63 to 10.15±0.92μm after a spontaneous resolution(P=0.27) and in IVB group was also reduced from 10.88±0.78 to 10.46±0.57μm.(P=0.46) No significant differences in the SFCT and MCV between both CSC groups were detected.
결론 : SFCT and mean choroidal volume in patients with CSC decreased both after spontaneous resolution and intravitreal bevacizumab. However, no significant differences in the SFCT and MCV between both CSC groups were detected.
|